FDA Approves Two Interchangeable Denosumab Biosimilars From Accord
The FDA approved Accord BioPharma's Osvyrti and Jubereq on November 20, and both are interchangeable with Amgen's Prolia and Xgeva across every shared use. Both labels carry a boxed warning on low blood calcium in advanced kidney disease.
Two biosimilars now match Prolia and Xgeva use for use, and pharmacies can swap them in.
The FDA approved Accord BioPharma's Osvyrti and Jubereq on November 20, 2026, and both denosumab biosimilars are interchangeable with their reference drugs.
Interchangeable is the operative word here. It means a pharmacist can substitute the biosimilar for the reference drug without a new prescriber order, under the same state rules that govern other interchangeable biosimilars.
Osvyrti references Prolia. It's a 60 mg/mL injection in a prefilled syringe, approved for postmenopausal women with osteoporosis at high risk of fracture, for men with osteoporosis, for glucocorticoid-induced osteoporosis, and for bone loss tied to hormone therapy for prostate and breast cancer.
Jubereq references Xgeva. It ships as a 120 mg vial, approved to prevent skeletal events in multiple myeloma and in bone metastases from solid tumors, to treat giant cell tumor of bone, and to treat high blood calcium from cancer that hasn't responded to bisphosphonates.
The safety label travels with both products. Each carries a boxed warning on severe hypocalcemia, dangerously low blood calcium, in patients with advanced chronic kidney disease, and the risk runs highest in patients on dialysis.
Osvyrti adds a second layer. The FDA approved it with a Risk Evaluation and Mitigation Strategy, a formal safety program that adds monitoring duties for prescribers and pharmacies.
Accord says the approvals rest on a phase 1 study and a phase 3 study that met their primary endpoints. The company hasn't announced launch pricing, and price is where biosimilars usually make their case.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.